D-pharm in new Chinese alliance, this time for anti-epileptic
This article was originally published in Scrip
Executive Summary
D-Pharm is keeping a steady eye on opportunities in China as its research portfolio moves forward, striking an out-licensing deal for another of its pipeline products for this burgeoning market.